GeoVax Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
About GeoVax Labs
Pharmaceutical Preparations, SIC 2834
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies against infectious diseases and solid tumors using novel proprietary platforms. The company's lead infectious disease candidate, GEO-MVA, targets mpox, smallpox, and other poxviruses, while its lead oncology program, Gedeptin, is a gene-directed enzyme prodrug therapy evaluated for advanced head and neck cancers. Additionally, the company develops GEO-CM04S1, a multi-antigen COVID-19 vaccine designed for immunocompromised individuals and booster applications, alongside preclinical vaccine programs targeting hemorrhagic fevers such as Ebola and Marburg viruses. GeoVax directs its solutions toward high-risk patient populations, healthcare providers, and public health or biodefense agencies.
The company operates in the United States, conducting clinical trials across multiple medical centers and maintaining collaborations with academic institutions and government agencies. GeoVax Labs is headquartered in Smyrna, Georgia, where its principal executive offices are located.
Summary of the business section of GeoVax Labs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GeoVax Labs, Inc.
- Headquarters
- Smyrna, GA
- Address
- 1955 Lake Park Drive, Suite 300
- Phone
- (678) 384-7220
- Employees
- 19, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WIPFLI LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- GOVX
- Exchange
- Nasdaq
- Shares outstanding
- 7M, Jul 27, 2026
- Public float
- $13.72M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Jan 12, 2026; 1-for-15 reverse, Jan 31, 2024; 1-for-500 reverse, May 13, 2019
- SEC CIK
- 832489
- CUSIP
- 373678705
- ISIN
- US3736787058
- LEI
- 549300KXK8Z4UZ4J7S86
- EIN
- 87-0455038
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David A. Dodd | President, CEO, Director | 36,661 |
| Mark Reynolds | CFO | 14,013 |
| Kelly T. McKee Jr. | Chief Medical Officer | 3,494 |
| John W. Sharkey | VP, Business Development | 6,191 |
| Mark J. Newman | Chief Scientific Officer | 3,000 |
| John N. Spencer Jr | Director | 21,402 |
| Jayne Morgan | Director | – |
| Dean G. Kollintzas | Director | 11,987 |
| Robert T. McNally | Director | 66,280 |
| Randal D. Chase | Director | 36,613 |
| Nicole Lemerond | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $840.69K | $372.92K | $506.07K | $2 | – |
| FY2024 | $645.80K | $642.38K | $495.76K | $26 | – |
| FY2023 | $384.20K | $334.06K | $326.27K | $57 | – |
| FY2022 | $652.01K | $293.26K | $429.38K | $10 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We currently have nineteen full-time employees.”
Corporate history
Events identified from SEC filings